You are here
Long-Acting Regimen of Cabotegravir and Rilpivirine Shows Sustained Virological Response and Good Tolerability in Patients with HIV
The injectable two-drug regimen of cabotegravir and rilpivirine (ViiV Healthcare, Brentford, England) could provide an alternative to daily tablets for patients with HIV, reducing the number of annual doses from 365 to 12.
Data from the LATTE-2 clinical trial showed durable treatment effects. At 160 weeks, 90% (n = 104/115) of patients who received the regimen every eight weeks and 83% (n = 95/115) of patients who received the regimen every four weeks remained virally suppressed. Patients in the oral comparator arm who switched to the injectable regimen at week 96 showed viral suppression rates of 97% (n = 33/34) and 100% (n = 10/10), respectively.
The most common adverse events included nasopharyngitis (38%), diarrhea (22%), and headache (22%). A majority of participants reported an injection-site reaction (ISR), 85% mild and 14% moderate, through week 160. Eighty-seven percent of ISRs resolved within seven days.